Compositions comprising bacterial strains
The invention provides compositions comprising one or more bacterial strains for treating preventing diarrhea and/or constipation.
1. A method of treating dyspepsia in a subject with irritable bowel syndrome (IBS) comprising administering to said subject a pharmaceutical composition that comprises at least 1×10 3 colony forming units (CFU) per gram of a bacteria strain of the genus Blautia with respect to a total weight of said pharmaceutical composition, wherein said bacteria strain comprises a 16S rRNA gene having at least 95% sequence identity to the polynucleotide sequence of SEQ ID NO:5, as determined by a Smith-Waterman homology search algorithm using an affine gap search with a gap open penalty of 12, a gap extension penalty of 2, and a Blocks Substitution Matrix (BLOSUM) of 62, wherein said administering is effective to treat said dyspepsia in said subject.
2. The method of claim 1 , wherein said pharmaceutical composition comprises from about 1×10 3 to about 1×10 11 CFU/g of said bacteria strain with respect to a total weight of said pharmaceutical composition.
3. The method of claim 1 , wherein said pharmaceutical composition comprises from about 1×10 9 to about 1×10 12 CFU of said bacteria strain.
4. The method of claim 1 , wherein said subject is a human.
5. The method of claim 1 , wherein said dyspepsia is functional dyspepsia.
6. The method of claim 1 , wherein said administering of said pharmaceutical composition is oral.
7. The method of claim 1 , wherein said administering of said pharmaceutical composition is rectal.
8. The method of claim 7 , wherein said pharmaceutical composition is formulated as a suppository.
9. The method of claim 8 , wherein the suppository comprises cocoa butter, suppocire, witepsol, glycero-gelatin, polyethylene glycol, or soap glycerin.
10. The method of claim 1 , wherein said bacteria strain is dried.
11. The method of claim 1 , wherein said pharmaceutical composition further comprises a lyoprotectant.
12. The method of claim 1 , wherein said subject is currently receiving an antibiotic treatment.
13. The method of claim 12 , wherein said antibiotic is fluoroquinolone, azithromycin, ciprofloxacin or rifaximin.
14. The method of claim 1 , wherein said IBS is associated with diarrhea.
15. The method of claim 1 , wherein said IBS is associated with constipation.
16. The method of claim 1 , wherein said IBS is associated with diarrhea and constipation.
17. The method of claim 1 , wherein said bacteria strain is of the species Blautia hydrogenotrophica.